References
- Kidd A, Okita N, Row W, et al. Immunologic aspects of Graves' and Hashimoto's diseases. Metabolism 1980: 29(1): 80–99
- Walfish PG, Farid NR. The immunogenic basis of autoimmune thyroid disease. In: Walfish PG, Wall JR, Volpe R, eds. Autoimmunity and the thyroid. Orlando. FL: Academic Press, 1985: 9–36
- Dunn JT. Choice of therapy in young adults with hyperthyroidism of Graves' disease: a brief, case-directed poll of fifty-four thyroidologists. Ann Intern Med 1984: 100(6): 891–3
- Cooper DS. Antithyroid drugs. N Engl J Med 1984: 311(21): 1353–62
- Stanley MM, Astwood EB. 1-Methyl-2-mescap- tolmidazole: an antithyroid compound highly active in man. Endocrinology 1949: 44(6): 588–9
- Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic damage.-induced hepatic damage. Arch Intern Med 1980: 140(9): 1184–5
- Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986: 63(1): 125–8
- Tamai H, Nakagawa T, Fukino O, et al. Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy. Ann Intern Med 1980: 92(4): 488–90
- Cooper DS. Which anti-thyroid drug? Am J Med 1986: 80(6): 1165–8
- Chopra LJ. A study of extrathyroidal conversion of thyroxine (T4) to 3,3′.5-triiodothyronine (T3) in vitro. Endocrinology 1977: 101(2): 453–63
- Milham S Jr, Elledge W. Maternal methimazole and congenital defects in children. Teratology 1972: 5(1): 125
- Graham GD, Barman KD. Radioiodine treatment of Graves' disease: an assessment of its potential risks. Ann Intern Med 1986: 105(6): 900–5